Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Antengene Announces Antibody-Drug Conjugate Granted Orphan Drug Designations by the FDA for the Treatment of Gastric and Pancreatic Cancers
Antengene Corporation, a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing […]
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
LaNova Medicines has announced it has entered into an exclusive license agreement with AstraZeneca, for […]
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701
Eisai announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical […]
Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and […]
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Tubulis and Bristol Myers Squibb today announced that they have entered into a strategic license […]
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more